Skip to main content
. 2018 Jul 13;13:4121–4132. doi: 10.2147/IJN.S171925

Figure 4.

Figure 4

In vivo evaluation of the therapeutic effect of PTX@Ac-DEX (n=6).

Notes: (A) Concentration of PTX in the CSF after intrathecal administration of PTX@Ac-DEX. (B) BBB grading score of SCI rats improved significantly in Taxol® and PTX@Ac-DEX group. (C) Semiquantification of NF200 indicated a promotion of axonal regeneration in Taxol and PTX@Ac-DEX group. (D) Semiquantification of CS56 indicated a suppression of CSPGs deposition in the lesion area after administration of Taxol or PTX@Ac-DEX. (E) Semiquantification of GFAP showed no significant difference in the volume of the lesion area among the four groups. (F) Representative immunohistochemical staining of NF200 (in red) and GFAP (in green) in spinal cord tissues at day 28 postinjury. (G) Representative immunohistochemical staining of CS56 (in red) and GFAP (in green) in spinal cord tissues at day 28 postinjury. ***P<0.001.

Abbreviations: Ac-DEX, acetalated dextran; BBB, Basso, Beattie, and Bresnahan; CSPG, chondroitin sulfate proteoglycans; PTX, paclitaxel; SCI, spinal cord injury; CSF, cerebrospinal fluid.